Korrelation von intravitrealen Zytokinen und OCT-Parametern bei Zentralvenenverschluss

Dacheva, Ivanka; Ceglowska, Karolina; Nobl, Matthias; Nowomiejska, Katarzyna; Kretz, Florian; Reich, Michael; Deuchler, Svenja; Tandogan, Tamer; Auffarth, Gerd U.; Koss, Michael

doi:10.1055/s-0041-105408

Cited by 6 publications

(14 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Анало-гичные изменения в стекловидном теле и влаге передней камеры также были описаны в ранее проводимых исследованиях [10,13,19,20,28].…”

Section: Discussionunclassified

“…Выявленный в результате исследования мак-симальный уровень VEGF-A и ET-1 как в сыво-ротке крови, так и в слезе у пациентов с ишемиче-ским типом окклюзии может свидетельствовать о зависимости их содержания от выраженности ишемии. Некоторые авторы также отмечают, что уровень некоторых цитокинов, вазоактивных ве-ществ и фактора роста напрямую зависит от типа ретинальной венозной окклюзии [5,10,19].…”

Section: Discussionunclassified

“…Учитывая, что IL-6 -много-функциональный провоспалительный цитокин, повышение его концентрации при окклюзии вен сетчатки подтверждает его значение в иммуно-патогенезе данного заболевания, что также было отмечено некоторыми авторами [10,13].…”

Section: таблица 2 концентрация цитокинов в слезной жидкости на фонеunclassified

“…Исследования, посвященные изуче-нию уровня VEGF-A при окклюзии вен сетчатки, установили значительное превышение его кон-центрации при данном заболевании в сравнении с группой контроля, а также прямую корреляци-онную связь уровня VEGF-A от давления и кон-центрации кислорода в окружающих тканях [10,13,19,28]. Однако недостаточно изученной оста-ется зависимость концентрации VEGF-A от типа ретинальной венозной окклюзии и динамика на фоне специфической терапии.…”

Section: Introductionunclassified

“…Иммуно-химические исследования выявили повышение содержания интерлейкина-6 (IL-6) в жидких средах глаза у пациентов с окклюзией вен сет-чатки с прямой корреляцией от площади пора-жения [10,13,27]. Однако неясна зависимость концентрации IL-6 от степени гипоксии сетчат-ки и динамика на фоне проводимого лечения.…”

Section: Introductionunclassified

See 4 more Smart Citations

Studies of Systemic and Local Cytokine Level in Retinal Vein Occlusion Associated With Antiangiogenic Therapy

Дроздова¹,

Khokhlova²,

Мезенцева³

et al. 2018

Med. immunol.

View full text Add to dashboard Cite

Section: Discussionunclassified

Section: таблица 2 концентрация цитокинов в слезной жидкости на фонеunclassified

Section: Introductionunclassified

See 3 more Smart Citations

Studies of Systemic and Local Cytokine Level in Retinal Vein Occlusion Associated With Antiangiogenic Therapy

Дроздова¹,

Khokhlova²,

Мезенцева³

et al. 2018

Med. immunol.

View full text Add to dashboard Cite

Choroidal thickening in retinal vein occlusion patients with serous retinal detachment

Chen

Yuan

Sun

et al. 2020

Graefes Arch Clin Exp Ophthalmol

View full text Add to dashboard Cite

Purpose To evaluate choroid thickness and macular retinal metrics in treatment naïve retinal vein occlusion (RVO) patients with serous retinal detachment (SRD) before and after intravitreal anti-vascular endothelial cell growth factor (VEGF) injection and to elucidate the possible role of choroid in the development of SRD and the potential role of SRD as a prognostic parameter. Methods This is a retrospective study involving 85 RVO patients, 41 central retinal vein occlusion (CRVO), and 44 branch retinal vein occlusion (BRVO), with macular edema: 21 central retinal vein occlusion and 22 branch retinal vein occlusion with SRD and the rest without SRD. Patients were evaluated with ophthalmic examinations and swept-source optical coherence tomography (SS-OCT) both before and 4-6 weeks after intravitreal anti-VEGF treatment. Choroid thickness and retinal metrics were measured and compared between SRD and non-SRD groups within each RVO subtype. Results In both CRVO and BRVO patients, the mean central subfield foveal thickness (CSFT) and central subfoveal choroid thickness (CSCT) of the SRD groups were thicker than those in the non-SRD groups (p < 0.05) at onset. After one anti-VEGF injection, CSFT and FNRT decreased in all groups (p < 0.05). The CSCTs were thicker in the SRD groups compared with the non-SRD groups (p < 0.05). The mean changes of CSFT were more remarkable in the SRD groups (p < 0.05). Conclusion Thicker choroid was a feature of naïve RVO patients with SRD and SRD may be an indicator of better anatomical recovery of retina in RVO patients after a single dose of anti-VEGF treatment.

show abstract

Effect of intravitreal ranibizumab on serous retinal detachment in branch retinal vein occlusion

Doğan

Sever

Çakır

et al. 2018

OPTH

View full text Add to dashboard Cite

PurposeThe aim of this study was to evaluate the effect of initial intravitreal ranibizumab injection on visual acuity (VA) and central macular thickness (CMT) for the treatment of macular edema (ME) with and without serous retinal detachment (SRD) secondary to branch retinal vein occlusion (BRVO).Materials and methodsFifty-two BRVO eyes, treated with intravitreal ranibizumab injection for ME with and without SRD, were retrospectively reviewed. Patients were divided into two groups according to spectral domain optical coherence tomography (SD-OCT). The efficacy of intravitreal ranibizumab injection at first month was assessed by analyzing the change in best-corrected VA and reduction in CMT with SD-OCT.ResultsThere were 21 patients with SRD and 31 patients with only CME (no-SRD). CMT was significantly greater in the SRD group than in the CME group (451±62.2 µm vs 383.5±37.2 µm, respectively, P<0.05). After initial intravitreal ranibizumab injection, mean VA improved from 0.87±0.26 logarithm of the minimum angle of resolution (LogMAR) to 0.54±0.27 LogMAR (P<0.01) and CMT decreased from 451±62.2 µm to 379.3±58.6 µm (P<0.001) in the SRD group. In the no-SRD group, mean VA improved from 0.69±0.25 LogMAR to 0.44±0.25 LogMAR (P<0.001) and the CMT decreased from 383.5±37.2 µm to 337.7±39.4 µm (P<0.001) at the first month visit. Eyes with SRD revealed better anatomic results and greater reduction of CMT after intravitreal ranibizumab injection (P<0.01).ConclusionVA and CMT can be improved by intravitreal ranibizumab injection in BRVO patients with and without SRD. However, more marked improvement in macular morphology was achieved in patients with SRD than those without SRD.

show abstract

Korrelation von intravitrealen Zytokinen und OCT-Parametern bei Zentralvenenverschluss

Abstract: The inflammatory cytokines were more often correlated with morphological changes assessed by SD-OCT, whereas VEGF-A did not correlate with CRVO-associated changes in SD-OCT. VEGF inhibition alone may not be sufficient to decrease the inflammatory response in CRVO therapy.

Cited by 6 publications

References 12 publications

Studies of Systemic and Local Cytokine Level in Retinal Vein Occlusion Associated With Antiangiogenic Therapy

Studies of Systemic and Local Cytokine Level in Retinal Vein Occlusion Associated With Antiangiogenic Therapy

Choroidal thickening in retinal vein occlusion patients with serous retinal detachment

Effect of intravitreal ranibizumab on serous retinal detachment in branch retinal vein occlusion

Contact Info

Product

Resources

About